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Background
Donor Lymphocyte infusion (DLI) is a therapy for the
patients with relapsed hematological malignancy after
allogeneic hematopoetic stem cell transplantation. How-
ever, the development of Graft-Versus-Host Disease
(GVHD) is a serious adverse event and the efficacy is lim-
ited when one needs to control the GVHD. To inhibit the
development of GVHD with increased tumor-specificity of
transferred allogeneic lymphocytes, here we demonstrate
the development of DLI with lymphocytes engineered to
express tumor-specific T cell receptor (TCR) in combina-
tion with decreased GVHD-inducing potential utilizing
the novel retrovirus vector (siTCR vector) that specifically
silences endogenous TCR in gene-engineered T cells.
Methods
Human PBMC were transduced with a high affinity TCR
specific to a cancer/testis antigen, NY-ESO-1, by the retro-
virus vector with siRNA specific to the endogenous TCR.
Resulting TCR gene-transduced T cells were examined for
their reactivity to allogeneic LCL by 3H uptake prolifera-
tion assay. Immunodeficient NOG mice were inoculated
with a NY-ESO-1-expressing human melanoma cell line
NW-MEL-38, received TCR gene-transduced T cells, and
monitored for tumor growth and the development of
GVHD.
Results
Human lymphocytes that were genetically engineered to
express a high affinity NY-ESO-1-specific TCR with
siTCR vector showed reduced expression of endogenous
TCR associated with the dramatically diminished reactivity
to allogeneic lymphocytes. When administrated into NOG
mice, these TCR gene-transduced T cells induced tumor
regression without the development of GVHD.
Conclusions
The results here suggest that the allogeneic T cells
transduced with a tumor-specific TCR by siTCR vector
showed diminished GVHD potential. These T cells will
be applicable to the donor lymphocytes infusion therapy
after allogeneic stem cell transplantation for the treat-
ment of hematological malignancy, providing diminished
GVHD and increased tumor eradication.
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